Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Indian Journal of Surgical Oncology
Erschienen in: Indian Journal of Surgical Oncology 1/2023

04.08.2022 | Review Article

Histopathological Evaluation and Molecular Diagnostic Tests for Peritoneal Metastases with Unknown Primary Site—a Review

verfasst von: Aditi Bhatt, Suniti Mishra, Olivier Glehen

Erschienen in: Indian Journal of Surgical Oncology | Sonderheft 1/2023

Einloggen, um Zugang zu erhalten

Abstract

Cancer of unknown primary (CUP) is a well-studied entity with guidelines available for the management of patients with CUP. The peritoneum represents one of the metastatic sites in CUP, and peritoneal metastases (PM) could present as CUP. PM of unknown origin remains a poorly studied clinical entity. There is only one series of 15 cases, one population-based study, and few other case reports on this subject. Studies on CUP, in general, cover some common tumour histological types like adenocarcinomas and squamous carcinomas. Some of these tumours may have a good prognosis though majority have high-grade disease with a poor long-term outcome. Some of the histological tumour types commonly seen in the clinical scenario of PM like mucinous carcinoma have not been studied. In this review, we divide PM into five histological types—adenocarcinomas, serous carcinomas, mucinous carcinomas, sarcomas and other rare varieties. We provide algorithms to identify the primary tumour site using immunohistochemistry when imaging, and endoscopy fails to establish the primary tumour site. The role of molecular diagnostic tests for PM or unknown origin is also discussed. Current literature on site-specific systemic therapy based on gene expression profiling does not show a clear benefit of this approach over empirical systemic therapies.
Literatur
1.
Glehen O, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L, Mansvelt B, Lorimier G, Msika S, Elias D (2010) Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Cancer 116:5608–5618. https://​doi.​org/​10.​1002/​cncr.​25356CrossRefPubMed
2.
3.
4.
Sebbag G, Shmookler BM, Chang D, Sugarbaker PH (2001) Peritoneal carcinomatosis from an unknown primary site. Management of 15 patients. Tumori 87(2):67–73PubMedCrossRef
5.
6.
7.
8.
9.
10.
Pavlidis N, Fizazi K (2005) Cancer of unknown primary (CUP). Crit Rev Oncol Hematol 54:243–250PubMedCrossRef
11.
Frost P (1991) Unknown primary tumours: an example of accelerated (type 2) tumor progression. Basic Life Sci 57:233–237PubMed
12.
Klein CA (2009) Parallel progression of primary tumours and metastases. Nat Rev Cancer 9(4):302–312PubMedCrossRef
13.
14.
Hayes-Jordan A, Green H, Lin H, Owusu-Agyemang P, Mejia R, Okhuysen-Cawley R, Cortes J, Fitzgerald NE, McAleer MF, Herzog C, Huh WW, Anderson P (2015) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for children, adolescents, and young adults: the first 50 cases. Ann Surg Oncol 22(5):1726–1732. https://​doi.​org/​10.​1245/​s10434-014-4289-yCrossRefPubMed
15.
16.
17.
18.
19.
20.
McCluggage WG (2002) Recent advances in immunohistochemistry in gynaecological pathology. Histopathology 46:309–326CrossRef
21.
McCluggage WG, Young RH (2005) Immunohistochemistry as a diagnostic aid in the evaluation of ovarian tumors. Semin Diagn Pathol 22:3–32PubMedCrossRef
22.
Ozcan A, Steven SS, Hamilton C, Anjana K, Coffey D, Krishnan B, Truong LD (2011) PAX 8 expression in non-neoplastic tissues, primary tumors, and metastatic tumors: a comprehensive immunohistochemical study. Mod Pathol 24:751–764PubMedCrossRef
23.
24.
Makrigiannakis A, Amin K, Coukos G, Tilly JL, Coutifaris C (2000) Regulated expression and potential roles of p53 and Wilms’ tumor suppressor gene (WT1) during follicular development in the human ovary. J Clin Endocrinol Metab 85(1):449–459PubMed
25.
Bárcena C, Oliva E (2011) WT1 expression in the female genital tract. Adv Anat Pathol 18(6):454–465PubMedCrossRef
26.
Liliac L, Carcangiu ML, Canevari S, Căruntu ID, Ciobanu Apostol DG, Danciu M, Onofriescu M, Amălinei C (2013) The value of PAX8 and WT1 molecules in ovarian cancer diagnosis. Rom J Morphol Embryol 54(1):17–27PubMed
27.
28.
29.
30.
31.
Dragomir A, de Wit M, Johansson C, Uhlen M, Ponten F (2014) The role of SATB2 as a diagnostic marker for tumors of colorectal origin: results of a pathology-based clinical prospective study. Am J Clin Pathol 141(5):630–638PubMedCrossRef
32.
33.
Brandler TC, Jelloul F, Soto D, Das K, Rosen L, Bhuiya TA (2015) Young investigator challenge: cadherin-17 and SATB2 in cytology specimens: do these new immunostains help in differentiating metastatic colorectal adenocarcinoma from adenocarcinomas of other origins? Cancer Cytopathol 123(12):706–713PubMedCrossRef
34.
35.
Goldstein NS, Bassi D (2001) Cytokeratins 7, 17, and 20 reactivity in pancreatic and ampulla of vater adenocarcinomas. Percentage of positivity and distribution is affected by the cut-point threshold. Am J Clin Pathol 115:695–702PubMedCrossRef
36.
Park SY, Kim HS, Hong EK et al (2002) Expression of cytokeratins 7 and 20 in primary carcinomas of the stomach and colorectum and their value in the differential diagnosis of metastatic carcinomas to the ovary. Hum Pathol 33:1078–1085PubMedCrossRef
37.
Ji H, Isacson C, Seidman JD et al (2002) Cytokeratins 7 and 20, Dpc4, and MUC5AC in the distinction of metastatic mucinous carcinomas in the ovary from primary ovarian mucinous tumors: Dpc4 assists in identifying metastatic pancreatic carcinomas. Int J Gynecol Pathol 21:391–400PubMedCrossRef
38.
Chhieng DC, Benson E, Eltoum I et al (2003) MUC1 and MUC2 expression in pancreatic ductal carcinoma obtained by fine-needle aspiration. Cancer 99:365–371PubMedCrossRef
39.
Nonaka D, Chiriboga L, Soslow RA (2008) Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas. Am J Surg Pathol 32:1566–1571PubMedCrossRef
40.
Tornos C, Soslow R, Chen S et al (2005) Expression of WT1, CA125, and GCDFP-15 as useful markers in the differential diagnosis of primary ovarian carcinomas versus metastatic breast cancer to the ovary. Am J Surg Pathol 29:1482–1489PubMedCrossRef
41.
Liu H, Shi J, Wilkerson ML et al (2012) Immunohistochemical evaluation of GATA3 expression in tumors and normal tissues: a useful immunomarker for breast and urothelial carcinomas. Am J Clin Pathol 138:57–64PubMedCrossRef
42.
Bhargava R, Beriwal S, Dabbs DJ (2007) Mammaglobin vs GCDFP-15: an immunohistologic validation survey for sensitivity and specificity. Am J Clin Pathol 127:103–113PubMedCrossRef
43.
Ruiz-Tovar J, Alonso HN, Morales CV, Lobo ME, Sanjuanbenito DA, Martinez ME (2007) Peritoneal carcinomatosis secondary to carcinoid tumour. Clin Transl Oncol 9:804–805PubMedCrossRef
44.
Mertz H, Vyberg M, Paulsen SM et al (1998) Immunohistochemical detection of neuroendocrine markers in tumors of the lungs and gastrointestinal tract. Appl Immunohistochem 6:175–180CrossRef
45.
Vasseur B, Cadiot G, Zins M et al (1996) Peritoneal carcinomatosis in patients with digestive endocrine tumors. Cancer 78:1686–1692PubMedCrossRef
46.
47.
Vinik AI, Thompson N, Eckhauser F, Moattari R (1989) Clinical features of carcinoid syndrome and the use of somatostatin analogue in its management. Acta Oncol 28:389–402PubMedCrossRef
48.
Gonzalez RS, Liu EH, Alvarez JR, Ayers GD, Washington MK, Shi C (2014) Should mesenteric tumor deposits be included in staging of well differentiated small intestine neuroendocrine tumors? Mod Pathol 27:1288–95PubMedPubMedCentralCrossRef
49.
Chambers AJ, Pasieka JL, Dixon E, Rorstad O (2010) Role of imaging in the preoperative staging of small bowel neuroendocrine tumors. J Am Coll Surg 211:620–627PubMedCrossRef
50.
Søreide O, Berstad T, Bakka A, Schrumpf E, Hanssen LE, Engh V, Bergan A, Flatmark A (1992) Surgical treatment as a principle in patients with advanced abdominal carcinoid tumors. Surgery 111:48–54PubMed
51.
Elias D, Lefevre JH, Duvillard P, Goéré D, Dromain C, Dumont F, Baudin E (2010) Hepatic metastases from neuroendocrine tumors with a thin slice CT scan and pathological examination: they are many more than you think. Ann Surg 251:307–10PubMedCrossRef
52.
Kimura N, Pilichowska M, Okamoto H et al (2000) Immunohistochemical expression of chromogranins A and B, prohormone convertases 2 and 3, and amidating enzyme in carcinoid tumors and pancreatic endocrine tumors. Mod Pathol 13:140–146PubMedCrossRef
53.
Al-Khafaji B, Noffsinger AE, Miller MA et al (1998) Immunohistologic analysis of gastrointestinal and pulmonary carcinoid tumors. Hum Pathol 29:992–9PubMedCrossRef
54.
Fahrenkamp AG, Wibbeke C, Winde G et al (1995) Immunohistochemical distribution of chromogranins A and B and secretogranin II in neuroendocrine tumours of the gastrointestinal tract. Virchows Arch 426:361–367PubMedCrossRef
55.
Sobin LH, Hjermstad BM, Sesterhenn IA et al (1986) Prostatic acid phosphatase activity in carcinoid tumors. Cancer 58:136–138PubMedCrossRef
56.
Barbareschi M, Roldo C, Zamboni G et al (2004) CDX-2 homeobox gene product expression in neuroendocrine tumors: its role as a marker of intestinal neuroendocrine tumors. Am J Surg Pathol 28:1169–1176PubMedCrossRef
57.
La Rosa S, Rigoli E, Uccella S et al (2004) CDX2 as a marker of intestinal EC-cells and related well-differentiated endocrine tumors. Virchows Arch 445:248–254PubMedCrossRef
58.
Jaffee IM, Rahmani M, Singhal MG et al (2006) Expression of the intestinal transcription factor CDX2 in carcinoid tumors is a marker of midgut origin. Arch Pathol Lab Med 130:1522–1526PubMedCrossRef
59.
Dabaja BS, Suki D, Pro B et al (2004) Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients. Cancer 101:518–26PubMedCrossRef
60.
Locher C, Malka D, Boige V et al (2005) Combination chemotherapy in advanced small bowel adenocarcinoma. Oncology 69:290–294PubMedCrossRef
61.
Overman MJ, Kopetz S, Wen S et al (2008) Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma. Cancer 113:2038–2045PubMedCrossRef
62.
Talamonti MS, Goetz LH, Rao S et al (2002) Primary cancers of the small bowel: analysis of prognostic factors and results of surgical management. Arch Surg 137:564–570PubMedCrossRef
63.
North JH, Pack MS (2000) Malignant tumors of the small intestine: a review of 144 cases. Am Surg 66:46–51PubMedCrossRef
64.
Frost DB, Mercado PD, Tyrell JS (1994) Small bowel cancer: a 30-year review. Ann Surg Oncol 1:290–295PubMedCrossRef
65.
Chen ZM, Ritter JH, Wang HL (2005) Differential expression of alpha-methylacyl coenzyme A racemase in adenocarcinomas of the small and large intestines. Am J Surg Pathol 29:890–896PubMedCrossRef
66.
Wong H, Chu P (2012) Immunohistochemical features of the gastrointestinal tract tumors. J Gastrointest Oncol 3(3):262–284PubMedPubMedCentral
67.
Johnson DE, Herndier BG, Medeiros LJ et al (1988) The diagnostic utility of the keratin profiles of hepatocellular carcinoma and cholangiocarcinoma. Am J Surg Pathol 12:187–197PubMedCrossRef
68.
69.
Al-Hussaini M, Stockman A, Foster H, McCluggage WG (2004) WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology 44(2):109–115PubMedCrossRef
70.
Sumathi VP, Al-Hussaini M, Connolly LE, Fullerton L, McCluggage WG (2004) Endometrial stromal neoplasms are immunoreactive with WT-1 antibody. Int J Gynecol Pathol 23(3):241–247PubMedCrossRef
71.
Shimizu M, Toki T, Takagi Y et al (2000) Immunohistochemical detection of the Wilms’ tumor gene (WT1) in epithelial ovarian tumors. Int J Gynecol Pathol 19:158–163PubMedCrossRef
72.
McCluggage WG (2004) WT1 is of value in ascertaining the site of origin of serous carcinomas within the female genital tract. Int J Gynecol Pathol 23:97–99PubMedCrossRef
73.
Chen W, Husain A, Nelson GS et al (2017) Immunohistochemical profiling of endometrial serous carcinoma. Int J Gynecol Pathol 36:128–139PubMedCrossRef
74.
McCluggage WG (2008) Immunohistochemical markers as a diagnostic aid in ovarian pathology. Diagn Histopathol 14(8):335–351CrossRef
75.
Davidson B (2008) New diagnostic and molecular characteristics of malignant mesothelioma. Ultrastruct Pathol 32:227–240PubMedCrossRef
76.
Battifora H, McCaughey WTE (1994) Tumors of the serosal membranes. Armed Forces Institute of Pathology, Washington DC
77.
Husain AN, Colby T, Ordonez N et al (2013) International Mesothelioma Interest Group. Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 137(5):647–667
78.
Delhorme JB, Severac F, Averous G, Glehen O, Passot G, Bakrin N, Marchal F, Pocard M, Lo Dico R, Eveno C, Carrere S, Sgarbura O, Quenet F, Ferron G, Goéré D, Brigand C, French National Network of Peritoneal Surface Malignancies (RENAPE) (2018) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei of appendicular and extra-appendicular origin. Br J Surg 105(6):668–676. https://​doi.​org/​10.​1002/​bjs.​10716CrossRefPubMed
79.
Bhatt A, Mishra S, Parikh L et al (2019) Essentials for pathological evaluation of peritoneal surface malignancies and synoptic reporting of cytoreductive surgery specimens—a review and evidence-based guide. Indian J Surg Oncol 332. https://​doi.​org/​10.​1007/​s13193-019-00897-7
80.
Vang R, Gown AM, Barry TS et al (2006) Cytokeratins 7 and 20 in primary and secondary mucinous tumors of the ovary: analysis of coordinate immunohistochemical expression profiles and staining distribution in 179 cases. Am J Surg Pathol 30:1130–1139PubMedCrossRef
81.
Liu Y, Ishibashi H, Hirano M, Takeshita K, Mizumoto A, Ichinose M, Nishino E, Kashu I, Yamamoto Y, Sugarbaker PH, Yonemura Y (2015) Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei arising from urachus. Ann Surg Oncol 22(8):2799–2805PubMedCrossRef
82.
Ronnett BM, Yemelyanova AV, Vang R et al (2008) Endocervical adenocarcinomas with ovarian metastases: analysis of 29 cases with emphasis on minimally invasive cervical tumours and the ability of the metastases to simulate primary ovarian neoplasms. Am J Surg Pathol 32:1835–1853PubMedCrossRef
83.
Cook DS, Attanoos RL, Jalloh SS, Gibbs AR (2000) “Mucin-positive” epithelial mesothelioma of the peritoneum: an unusual diagnostic pitfall. Histopathology 37:33–36PubMedCrossRef
84.
Facchetti F, Lonardi S, Gentili F et al (2007) Claudin 4 identifies a wide spectruof epithelial neoplasms and represents a very useful marker for carcinoma versus mesothelioma diagnosis in pleural and peritoneal biopsies and effusions. Virchows Arch 451:669–680PubMedCrossRef
85.
Facchetti F, Gentili F, Lonardi S, Bercich L, Santin A (2007) Claudin-4 in mesothelioma diagnosis. Histopathology 51:261–263PubMedCrossRef
86.
87.
Diaz L, Okonkwo A, Solans EP, Bedrossian C, Rao MS (2002) Extensive myxoid change in well differentiated papillary mesothelioma of the pelvic peritoneum. Ann Diagn Pathol 6:164–167PubMedCrossRef
88.
Bhatt A, Ramakrishnan AS (2018) Rare indications for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. In: Bhatt A. (eds) Management of peritoneal metastases- cytoreductive surgery, HIPEC and beyond. Springer, Singapore
89.
90.
Lee CH, Ou WB, Marino-Enriquez A et al (2012) 14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma. Proc Natl Acad Sci U S A 109:929–934PubMedPubMedCentralCrossRef
91.
Chang KL, Crabtree GS, Lim-Tan SK et al (1990) Primary uterine endometrial stromal neoplasms. A clinicopathologic study of 117 cases. Am J Surg Pathol 14:415-438. 2PubMedCrossRef
92.
Evans HL (1982) Endometrial stromal sarcoma and poorly differentiated endometrial sarcoma. Cancer 50:2170–2182PubMedCrossRef
93.
Hendrickson MR, Tavassoli FA, Kempson RL (2003) Mesenchymal tumours and related lesions. In: . World HealthOrganization Classification of Tumours Pathology and Genetics of Tumours of the Breast and Female Genital Organ Lyon, France: IARC Press
94.
Norris HJ, Taylor HB (1966) Mesenchymal tumors of the uterus. I. A clinical and pathological study of 53 endometrial stromal tumors. Cancer 19:755–766PubMedCrossRef
95.
Chu PG, Arber DA, Weiss LM et al (2001) Utility of CD10 in distinguishing between endometrial stromal sarcoma and uterine smooth muscle tumors: an immunohistochemical comparison of 34 cases. Mod Pathol 14:465–471PubMedCrossRef
96.
McCluggage WG, Sumathi VP, Maxwell P (2001) CD10 is a sensitive and diagnostically useful immunohistochemical marker of normal endometrial stroma and of endometrial stromal neoplasms. Histopathology 39:273–278PubMedCrossRef
97.
Lee CH, Marino-Enriquez A, Ou W et al (2012) The clinicopathologic features of YWHAE-FAM22 endometrial stromal sarcomas: a histologically high-grade and clinically aggressive tumor. Am J Surg Pathol 36:641–653PubMedCrossRef
98.
Lee CH, Ali RH, Rouzbahman M et al (2012) Cyclin D1 as a diagnostic immunomarker for endometrial stromal sarcoma with YWHAE-FAM22 rearrangement. Am J Surg Pathol 36:1562–1570PubMedPubMedCentralCrossRef
99.
Klein WM, Kurman RJ (2003) Lack of expression of c-kit protein (CD117) in mesenchymal tumors of the uterus and ovary. Int J Gynecol Pathol 22:181–184PubMedCrossRef
100.
Nakayama M, Mitsuhashi T, Shimizu Y et al (2006) Immunohistochemical evaluation of KIT expression in sarcomas of the gynecologic region. Int J Gynecol Pathol 25(70–76):59
101.
Caudell JJ, Deavers MT, Slomovitz BM et al (2005) Imatinib mesylate (gleevec)–targeted kinases are expressed in uterine sarcomas. Appl Immunohistochem Mol Morphol 13:167–170PubMedCrossRef
102.
Lee CH, Liang CW, Espinosa I (2010) The utility of discovered on gastrointestinal stromal tumor 1 (DOG1) antibody in surgical pathology-the GIST of it. Adv Anat Pathol 17:222–232PubMedCrossRef
103.
Hendrickson MR, Tavassoli FA, Kempson RL et al (2003) Mesenchymal tumours and related lesions. In: Tavassoli FA, Devilee P (eds) World Health Organization classification of tumours: pathology and genetics of tumours of the breast and female genital organs. IARC Press, Lyon, pp 236–243
104.
Oliva E, Young RH, Amin MB et al (2002) An immunohistochemical analysis of endometrial stromal and smooth muscle tumors of the uterus: a study of 54 cases emphasizing the importance of using a panel because of overlap in immunoreactivity for individual antibodies. Am J Surg Pathol 26:403–412PubMedCrossRef
105.
Rizeq MN, van de Rijn M, Hendrickson MR et al (1994) A comparative immunohistochemical study of uterine smooth muscle neoplasms with emphasis on the epithelioid variant. Hum Pathol 25:671–677PubMedCrossRef
106.
Bodner-Adler B, Bodner K, Czerwenka K et al (2005) Expression of p16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis. Gynecol Oncol 96:62–66PubMedCrossRef
107.
Atkins KA, Arronte N, Darus CJ et al (2008) The use of p16 in enhancing the histologic classification of uterine smooth muscle tumors. Am J Surg Pathol 32(98–102):39
108.
O’Neill CJ, McBride HA, Connolly LE et al (2007) Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential. Histopathology 50(851–858):41
109.
de Vos S, Wilczynski SP, Fleischhacker M et al (1994) p53 alterations in uterine leiomyosarcomas versus leiomyomas. Gynecol Oncol 54(205–208):43
110.
Blom R, Guerrieri C, Stal O et al (1998) Leiomyosarcoma of the uterus: a clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 49 cases. Gynecol Oncol 68(54–61):42
111.
Jeffers MD, Farquharson MA, Richmond JA et al (1995) p53 immunoreactivity and mutation of the p53 gene in smooth muscle tumours of the uterine corpus. J Pathol 177:65–70PubMedCrossRef
112.
Hall KL, Teneriello MG, Taylor RR et al (1997) Analysis of Ki-ras, p53, and MDM2 genes in uterine leiomyomas and leiomyosarcomas. Gynecol Oncol 65(330–335):44
113.
Lasota J, Jasinski M, Sarlomo-Rikala M et al (1999) Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol 154:53–60PubMedPubMedCentralCrossRef
114.
Tanimura TC, Nohara M et al (1980) Primary leiomyosarcoma of the omentum. Kurume Med J 27:101–105PubMedCrossRef
115.
Tsurumi H, Okada S, Koshino Y, Oyama M, Higaki H, Shimokawa K, Yamauchi O, Moriwaki H, Muto Y (1991) A case of leiomyoblastoma (epithelioid leiomyosarcoma) of the greater omentum Gastroenterol. Jpn 26(3):370–375
116.
Mahon DE, Carp NZ, Goldhahn RT et al (1993) Primary leiomyosarcoma of the greater omentum: case report and review of the literature Am. Surg 59:160–163
117.
118.
Ishida H, Ishida J (1998) Primary tumours of the greater omentum. Eur Radiol 8(9):1598–1601PubMedCrossRef
119.
Scwartz RW, Reames M, McGrath PC et al (1991) Primary solid neoplasms of the greater omentum. Surgery 109:543–549
120.
Stout AP, Hendry J, Purdie FJ (1963) Primary solid tumours of the greater omentum. Cancer 16:231–243PubMedCrossRef
121.
Fattar S, Morton PCG, Schulman A et al (1981) Radiological diagnosis of primary greater omental mass lesion Clin. Radiol 32:325–330
122.
Weinberger HA, Ahmed MS (1997) Mesenchymal solid tumors of the omentum. Surgery 82:754–759
123.
Virchow R (1863) Die Krankhaften Geschwülste. Berlin, Germany, Springer, Google Scholar
124.
Ewing J (1919) Neoplatic diseases. W.B. Saunders, Philadelphia, PA
125.
Zhao S, Bellone S, Lopez S, Thakral D, Schwab C, English DP, Black J et al (2016) Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition. Proc Natl Acad Sci U S A 113(43):12238–12243. https://​doi.​org/​10.​1073/​pnas.​1614120113
126.
Wada H, Enomoto T, Fujita M et al (1997) Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumours. Cancer Res 57:5379–5385PubMed
127.
Banik T, Halder D, Gupta N, Dey P Malignant mixed Mullerian tumor of the uterus: diagnosis of a case by fine-needle aspiration cytology and review of literature. Diagnostic Cytopathology. In press
128.
Ahuja A, Safaya R, Prakash G, Kumar L, Shukla NK (2011) Primary mixed Mullerian tumor of the vagina—a case report with review of the literature. Pathol Res Pract 207(4):253–255PubMedCrossRef
129.
Sharma NK, Sorosky JI, Bender D, Fletcher MS, Sood AK (2005) Malignant mixed Mullerian tumor (MMMT) of the cervix. Gynecol Oncol 97(2):442–445PubMedCrossRef
130.
Duman BB, Kara IO, Gunaldi M, Ercolak V (2011) Malignant mixed Mullerian tumor of the ovary with two cases and review of the literature. Arch Gynecol Obstet 283(6):1363–1368PubMedCrossRef
131.
Shen YM, Xie YP, Xu L et al (2010) Malignant mixed Mullerian tumor of the fallopian tube: report of two cases and review of literature. Arch Gynecol Obstet 281(6):1023–1028PubMedCrossRef
132.
Brown L (2008) Pathology of uterine malignancies. Clin Oncol 20(6):433–447CrossRef
133.
134.
Mok JE, Kim YM, Jung MH, Kim KR, Kim DY, Kim JH et al (2006) Malignant mixed Mullerian tumors of the ovary: experience with cytoreductive surgery and platinum-based combination chemotherapy. Int J Gynecol Cancer 16:101–105PubMedCrossRef
135.
Boucher D, Tetu B (1994) Morphologic prognostic factors of malignant mixed Mullerian tumors of the ovary: a clinicopathologic study of 15 cases. Int J Gynecol Pathol 13(1):22–28PubMedCrossRef
136.
137.
Flanagan M et al (2018) Peritoneal metastases from extra-abdominal cancer — a population-based study. Eur J Surg Oncol 44:1811–1817PubMedCrossRef
138.
139.
140.
Fizazi K, Greco FA, Pavlidis N, Daugaard G, Oien K, Pentheroudakis G et al (2015) Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(Suppl 5):v133–v138PubMedCrossRef
141.
Bridgewater J et al (2008) Gene expression profiling may improve diagnosis in patients with carcinoma of unknown primary. Br J Cancer 98:1425–1430PubMedPubMedCentralCrossRef
142.
Pillai R et al (2011) Validation and reproducibility of a microar- ray-based gene expression test for tumor identification in formalin-fixed, paraffin-embedded specimens. J Mol Diagn 13:48–56PubMedPubMedCentralCrossRef
143.
Varadhachary GR et al (2008) Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol 26:4442–4448PubMedCrossRef
144.
Hainsworth JD et al (2013) Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute. J Clin Oncol 31:217–223PubMedCrossRef
145.
Fizazi K et al (2019) LBA15_PR a phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04). Ann. Oncol 30:mdz394CrossRef
146.
147.
Ross JS et al (2015) Comprehensive genomic profiling of carcinoma of unknown primary site: new routes to targeted therapies. JAMA Oncol 1:40–49PubMedCrossRef
148.
Tothill RW et al (2013) Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary. J Pathol 231:413–423PubMedCrossRef
149.
Gatalica Z et al (2018) Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy. Eur J Cancer 94:179–186PubMedCrossRef
150.
151.
Gatalica Z et al (2014) Comprehensive tumor profiling identifies numerous biomarkers of drug response in cancers of unknown primary site: analysis of 1806 cases. Oncotarget 5:12440–12447PubMedPubMedCentralCrossRef
152.
Varghese AM et al (2017) Clinical and molecular characterization of patients with cancer of unknown primary in the modern era. Ann Oncol 28:3015–3021PubMedPubMedCentralCrossRef
153.
Kato S et al (2017) Utility of genomic analysis in circulating tumor DNA from patients with carcinoma of unknown primary. Cancer Res 77:4238–4246PubMedPubMedCentralCrossRef
154.
155.
156.
157.
Joseph NM, Chen YY, Nasr A et al (2017) Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X. Mod Pathol 30:246–254PubMedCrossRef
158.
159.
160.
161.
162.
Hayashi H et al (2019) Randomized phase II trial comparing site-specific treatment based on gene expression profiling with carboplatin and paclitaxel for patients with cancer of unknown primary site. J Clin Oncol 37:570–579PubMedCrossRef
163.
Franko, J, Shi, Q, Meyers, JP et al. (17 more authors) (2016) Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncol 17(12). pp. 1709–1719. ISSN 1470–2045. https://​doi.​org/​10.​1016/​S1470-2045(16)30500-9
164.
165.
Ubink I, van Eden WJ, Snaebjornsson P, Kok NFM, van Kuik J, van Grevenstein WMU, Laclé MM, Sanders J, Fijneman RJA, Elias SG, Borel Rinkes IHM, Aalbers AGJ, Kranenburg O (2018) Histopathological and molecular classification of colorectal cancer and corresponding peritoneal metastases. Br J Surg 105(2):e204–e211. https://​doi.​org/​10.​1002/​bjs.​10788CrossRefPubMed
Metadaten
Titel
Histopathological Evaluation and Molecular Diagnostic Tests for Peritoneal Metastases with Unknown Primary Site—a Review
verfasst von
Aditi Bhatt
Suniti Mishra
Olivier Glehen
Publikationsdatum
04.08.2022
Verlag
Springer India
Erschienen in
Indian Journal of Surgical Oncology / Ausgabe Sonderheft 1/2023
Print ISSN: 0975-7651
Elektronische ISSN: 0976-6952
DOI
https://doi.org/10.1007/s13193-022-01612-9

Weitere Artikel der Sonderheft 1/2023

Indian Journal of Surgical Oncology 1/2023 Zur Ausgabe

Original Article

Updated Incidence, Treatment and Survival of a Nationwide Cohort of Patients with Peritoneal Metastases of Unknown Origin

Review Article

Peritoneal Surface Malignancies Originating From Urachal Carcinoma: Case Reports and Review of the Literature

Original Article

An Asian Tertiary Centre’s Early Experience with Laparoscopic Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis

Original Article

Can EPIC Be a Low-Cost Alternative to HIPEC in Advanced Epithelial Ovarian Cancer in Resource-Constraint Settings? Experience from Tertiary Care Oncology Center

Review Article

Appendiceal Goblet Cell Carcinoma: Role of Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

Original Article

Long-Term Survival in Patients Treated by Cytoreductive Surgery with or Without HIPEC for Peritoneal Surface Malignancies—A report from the Indian HIPEC Registry

Neu im Fachgebiet Chirurgie

Deutlich weniger Infektionen: Wundprotektoren schützen!

08.05.2024 Postoperative Wundinfektion Nachrichten

Der Einsatz von Wundprotektoren bei offenen Eingriffen am unteren Gastrointestinaltrakt schützt vor Infektionen im Op.-Gebiet – und dient darüber hinaus der besseren Sicht. Das bestätigt mit großer Robustheit eine randomisierte Studie im Fachblatt JAMA Surgery.

Chirurginnen und Chirurgen sind stark suizidgefährdet

07.05.2024 Suizid Nachrichten

Der belastende Arbeitsalltag wirkt sich negativ auf die psychische Gesundheit der Angehörigen ärztlicher Berufsgruppen aus. Chirurginnen und Chirurgen bilden da keine Ausnahme, im Gegenteil.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.
Bildnachweise